2017
Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV
Aghourian M, Legault-Denis C, Soucy J, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard M. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Molecular Psychiatry 2017, 22: 1531-1538. PMID: 28894304, DOI: 10.1038/mp.2017.183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBrainCase-Control StudiesCholinergic AgentsCholinergic NeuronsFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPiperidinesPositron-Emission TomographyPresynaptic TerminalsRadioactive TracersVesicular Acetylcholine Transport ProteinsConceptsMini-Mental State ExaminationStandardized uptake value ratioAlzheimer's diseaseCortical areasPresynaptic cholinergic nerve terminalsAmyloid-beta tracerNumerous cortical areasCognitive scalesCholinergic nerve terminalsUptake value ratioVesicular acetylcholine transporterMultiple cortical areasNew PET radiotracersVoxel-wise t-testsCholinergic denervationCholinergic terminalsCholinergic degenerationControl subjectsAD patientsCholinergic lossNerve terminalsAD groupHealthy subjectsAcetylcholine transporterAD subjects
2011
Brain Regionalα-[11C]Methyl-L-Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder
Berney A, Leyton M, Gravel P, Sibon I, Sookman D, Neto P, Diksic M, Nakai A, Pinard G, Todorov C, Okazawa H, Blier P, Nordahl T, Benkelfat C. Brain Regionalα-[11C]Methyl-L-Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder. JAMA Psychiatry 2011, 68: 732-741. PMID: 21383250, PMCID: PMC3677917, DOI: 10.1001/archgenpsychiatry.2011.16.Peer-Reviewed Original ResearchConceptsL-tryptophan trappingObsessive-compulsive disorderMedication-free patientsHealthy controlsMcGill University Health CentreGlucose metabolic disturbancesAdults meeting criteriaMain outcome measuresUniversity Health CentrePositron emission tomographyDepartment of PsychiatryStatistical parametric mappingTemporal lobe activityMontreal Neurological InstituteSerotonergic componentReuptake inhibitorsSerotonin dysfunctionClinical efficacySerotonergic abnormalitiesMetabolic disturbancesPostsynaptic changesSymptomatic stateSerotonergic systemHealth centersOutcome measures